With the present study we demonstrate that chronic treatment of STZ-treated rats with the SGLT2i empagliflozin prevents the development of endothelial dysfunction, oxidative stress, AGE/RAGE signaling and inflammation in a well characterized animal model of type I diabetes mellitus. The gene discussed is AGER; the disease is type 1 diabetes mellitus.